Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy

Trial Profile

A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2019

At a glance

  • Drugs Atezolizumab (Primary) ; Cabozantinib (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms COSMIC-312
  • Sponsors Exelixis
  • Most Recent Events

    • 06 Dec 2018 New trial record
    • 05 Dec 2018 According to an Ipsen media release, Ipsen will co-fund the trial. Ipsen will have access to the results to support potential future regulatory submissions outside of the U.S. and Japan. Genentech, is providing atezolizumab for use in this trial.
    • 05 Dec 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top